Introduction
============

The prevalence of fatty liver diseases in developed countries has increased dramatically and becomes a serious health problem. Non-alcoholic fatty liver diseases (NAFLD) has prevalence as high as 20-40% in general population and accounts for 75% incidence of obesity or diabetes in Western countries [@B1]. In UK, alcohol-related liver diseases is responsible for over a third (37%) of deaths associated with liver diseases [@B2]. Metabolic homeostasis disruption is mostly likely to be responsible for this global epidemic of fatty liver diseases, and most cases of fatty liver diseases are commonly associated with metabolic syndromes, such as hyperlipidemia and insulin resistance, and are frequently linked with other metabolic diseases like obesity and type 2 diabetes mellitus [@B3]. In clinical practice, fatty liver diseases encompass a continued spectrum of liver damage, which progresses from simple hepatic steatosis to advanced steatohepatitis, and in some cases, even to fibrosis, cirrhosis, and hepatocellular carcinoma [@B4], [@B5].

In recent years, accumulating evidences indicate that sirtuins play important roles in regulating the fatty liver diseases related metabolic processes. Sirtuins are a group of highly conserved NAD^+^ dependent histone and protein deacetylases and/or ADP-ribosyl transferases that play important functions in numerous biological processes [@B6]-[@B17]. Sirtuins are named because of their homology to *Saccharomyces cerevisiae* gene silent information regulation-2 (Sir2) and grouped as class III histone deacetylases (HDACs) [@B18], [@B19]. To date, there are seven mammalian homolegs of sirtuin (SIRT1-7) have been reported, which are located in different subcellular regions, i.e. the nucleus (SIRT1, 2, 6 and 7), the cytoplasm (SIRT1 and 2), and the mitochondria (SIRT3, 4 and 5) [@B20]. While several members of sirtuin family are implicated in various aspects of fatty liver [@B21]-[@B26], SIRT1 is the most extensively studied member, and is involved in both NAFLD and alcoholic fatty liver diseases (AFLD) [@B22], [@B27]-[@B32]. In this review, we will summarize the latest advances about roles of SIRT1 in fatty liver diseases, with a focus on how SIRT1 regulates lipid metabolism, oxidative stress and inflammation in the liver. We will also discuss the potential applications of SIRT1 activators as therapeutic agents for fatty liver diseases treatment.

Pathology of fatty liver diseases
=================================

The main reasons causing fatty liver diseases are due to the popular high-fat/calorie diet or heavy alcohol intake, which lead to NAFLD or AFLD respectively [@B4], [@B6], [@B33], [@B34]. The initial early stage of fatty liver diseases is hepatic steatosis, which is characterized by excessive triglyceride (TG) deposition as lipid droplets in hepatocytes [@B35]. Abnormal cytoplasmic lipid accumulation in the liver is primarily caused by imbalance of hepatic lipid homeostasis between TG/fatty acids acquisition and removal, which involves increased fatty acids/TG uptake, enhanced *de novo*lipogenesis, impaired fatty acids β-oxidation, and/or decreased lipid export as the form of very low-density lipoprotein (VLDL) in liver [@B4], [@B35], [@B36].

Hepatic TG acquisition is generally derived from three sources, including diet, *de novo* synthesis and adipose tissue. Under high-fat diet, dietary fats taken up in the intestine are delivered into blood circulation as TG-rich chylomicrons and free fatty acids (FFA), and about 20% of them are delivered into the liver by hepatic lipid uptake [@B35], [@B37]. Under high-calorie diet, carbohydrate intake increases circulating glucose and insulin levels, further promotes *de novo*lipogenesis from acetyl-coenzyme A (CoA) through activating transcription factor carbohydrate response element binding protein (ChREBP) and sterol regulatory element binding protein-1c (SREBP-1c) [@B38], [@B39]. With heavy alcohol intake regardless of long-term or short-term, lipolysis in white adipose tissue is stimulated through activating the lipases, adipose triglyceride lipase (ATGL) and hormone sensitive lipase (HSL), to release FFA into the circulation, meanwhile hepatic fatty acids (FA) uptake capability is also evaluated through overexpressing FA-transport proteins, including fatty acid translocase 36 (CD36) and fatty acid transporter proteins (FATPs) [@B40]-[@B42]. In addition, alcohol exposure and high-fat diet could promote hepatic *de novo*lipogenesis as well [@B36], [@B43]. Acquired FFA in liver has three possible fates, as shown in figure [1](#F1){ref-type="fig"}. It can be metabolized by β-oxidation in mitochondria to produce energy and ketone bodies mainly through peroxisome proliferator-activated receptor alpha (PPARα) and peroxisome proliferator-activated receptor-gamma co-activator 1 alpha (PGC-1α) signaling regulation, esterified to TG and stored in lipid droplets, or packaged with apolipoprotein B (ApoB) and secreted into blood circulation as the form of VLDL [@B35]. The imbalance of hepatic TG/fatty acids flux acquisition and removal consequently causes steatosis in the liver (Figure [1](#F1){ref-type="fig"}).

Clinically, fatty liver diseases always encompass a continued spectrum of liver damages: benign hepatic steatosis, steatohepatitis, fibrosis, cirrhosis, and end-stage liver diseases [@B4], [@B5]. For NAFLD only, about one-third of NAFLD patients who undergo histological biopsy have the evidence of steatohepatitis, of whom, 10% to 30% progress to fibrosis and cirrhosis within 10 years [@B44], [@B45]. In addition to acting as the first hit to induce steatosis, accumulated large amounts of lipid droplets in the liver also trigger mitochondrial oxidative stress characterized by abundant reactive oxygen species (ROS) production, and hepatic inflammation with large cytokine production, particularly tumor necrosis factor α (TNF-α) and interleukin 6 (IL-6), which are considered as critical factors or hits leading to the progression from simple steatosis to advanced steatohepatitis or even fibrosis and cirrhosis [@B4], [@B46]-[@B48]. In addition, the hepatic inflammation is also contributed by circulating cytokines secreted from adipose tissue, and both high-fat/calorie diet and heavy alcohol intake are able to trigger significant inflammation in adipose tissue [@B49]-[@B52]. As summarized in figure [1](#F1){ref-type="fig"} & [2](#F2){ref-type="fig"}, aberrant lipid metabolism and accumulated oxidative stress/inflammation levels are important factors that promote TG deposition in the liver and the progression of fatty liver diseases from steatosis to advanced stage.

Mammalian SIRT1
===============

SIRT1 functions by cleaving the nicotinamideribosyl bond of NAD^+^ and transfering the acetyl group from the substrate\'s lysine side chain to NAD^+^, thereby generating nicotinamide, 2\'-O-acetyl-ADP-ribose and a deacetylated substrate [@B53]-[@B55]. As NAD^+^is required as a co-substrate in this process, SIRT1 activity can be activated by increasing intracellular NAD^+^ levels, and inhibited by high nicotinamide levels [@B56]. Increasing evidences demonstrated that SIRT1 acts as a key metabolic/energy sensor, which directly couples the cellular metabolic/energy status (via intracellular NAD^+^/NADH ratio) to transcriptional activity and/or gene expression of several crucial transcription factor and transcription co-activators that are involved in metabolic homeostasis [@B6], [@B18], [@B55], [@B57], [@B58]. These includes ChREBP, SREBP-1c, peroxisome proliferator-activated receptor alpha (PPARα), peroxisome proliferator-activated receptor-gamma co-activator 1 alpha (PGC-1α), nuclear factor-κB (NF-κB) and so on.

Of note, it is known that some factors, such as alcohol, high-fat diet, and high-calorie diet, could impair functions of SIRT1. The mechanisms underlying how these factors affect SIRT1 are complex, and may involved multiple ways. But experimental evidence indicates that one of the major factors is NAD^+^, which affects SIRT1 activity. In this regards, it was reported that alcohol consumption could result in decreased NAD^+^/NADH ratio as well as SIRT1 activity in hepatocytes [@B31], [@B59]. During alcohol metabolism, alcohol is firstly metabolized by either alcohol dehydrogenase (ADH) in the cytosol or cytochrome P450 IIE1 (CYP2E1) in the endoplasmic reticulum to produce acetaldehyde, which is further rapidly metabolized by mitochondrial aldehyde dehydrogenase (ALDH2) to form acetate and convert NAD^+^ to NADH [@B60], [@B61]. Moreover, reduced NAD^+^ level and SIRT1 activity were concomitant with dietary energy/nutrition overload status such as high-fat diet and/or high-calorie diet feeding conditions [@B62]-[@B64], whereas calorie restriction could increase NAD^+^ level and induce SIRT1 activation [@B65], [@B66]. Besides affecting NAD^+^ level, it was also recently observed that aging could aggravate alcoholic liver diseases through down-regulating SIRT1 protein although the underlying mechanism remains elusive [@B59]. Given the NAD^+^ dependency of SIRT1, SIRT1 therefore servers as important metabolic sensor, which couples alcohol, high-fat diet and high-calorie diet intake with corresponding lipid/energy homeostasis signaling in the liver and other associated organs.

Role of SIRT1 in fatty liver diseases: phenotype of SIRT1 deficient and transgenic mice
=======================================================================================

The function of SIRT1 in fatty liver formation was first studied in mice with an albumin-Cre (Alb-Cre) mediated liver-specific deletion of exon 4 of the *Sirt1* gene [@B28], [@B67]. The mutant mice (*Sirt1^flox4/flox4^;Alb-Cre*) had no obvious abnormality under regular feeding condition, however, displayed either attenuated [@B67] or accelerated [@B28] hepatic steatosis when they were fed with high-fat diet. While this discrepancy is not clear, Wang *et al.* generated and studied mice carrying liver-specific deletion of exons 5 and 6 of *Sirt1*gene mediated by Alb-Cre (*Sirt1*^flox5-6/flox5-6^*;Alb-Cre*, or *Sirt1*^LKO^) [@B68]. The data indicate that as early as 2 months, 28.6% (2/7) of *Sirt1*^LKO^ mice have started to accumulate lipid droplet (Figure [3](#F3){ref-type="fig"}A). At 6 months, 55.9% (5/9) of them have developed fatty liver. The frequency of fatty liver is increased to 77.8% (7/9) when the *Sirt1*^LKO^ mice at 14 months age, whereas only 16.6% (2/12) control mice suffered fatty liver during the same time (Figure [3](#F3){ref-type="fig"}A, B). Consistent with the increased lipid deposition, significant higher TG content level in liver and plasma are also observed in mutant mice than in controls (Figure [3](#F3){ref-type="fig"}C, E), plasma FFA level also increased in mutant mice compared to controls but without significance (Figure [3](#F3){ref-type="fig"}D). These data provide the direct evidences that SIRT1 deficiency in the liver induce fatty liver diseases even without high-fat diet. Accompanied with hepatic steatosis development, the *Sirt1*^LKO^ mice also exhibited hyperglycemia and insulin resistance due to increased hepatic gluconeogenesis, and are associated with increased intracellular ROS accumulation in multiple tissues, including liver, adipose tissue, skeletal muscle and spleen [@B69]. These data indicate that liver specific disruption of SIRT1 not only causes hepatic steatosis but also promotes the progression to advanced metabolic disorder stage. A recent study on human fetal hepatocytes treated with sirtinol, a pharmacological inhibitor of SIRT1, confirmed the finding from *Sirt1*^LKO^ mice about lipid and glucose accumulation in hepatocytes induced by SIRT1 deficiency [@B70].

A recent study also showed that *Sirt1*^flox4/flox4^*;Alb-Cre* mice challenged with alcohol-containing diet exacerbated the fatty liver formation when compared with controls, as well as the inflammatory cytokines production [@B29]. Similar effect of SIRT1 on steatosis and inflammation aggravation is also reported in SIRT1 whole-body heterozygous mice under mediate- or high-fat diet feeding condition [@B27]. Conversely, overexpression of SIRT1 could protect *Sirt1* transgenic mice from high-fat diet induced hepatic steatosis, hepatic glucose intolerance, and hepatic inflammation [@B30]. Taken together, all these phenotypic evidences from either SIRT1 deficient or transgenic mice, as summarized in table [1](#T1){ref-type="table"}, demonstrate that SIRT1 play important roles in negatively regulating fatty liver diseases initiation and progression. In the following parts, we will specifically review the underlying mechanism in detail.

Role of SIRT1 in hepatic lipid metabolism
=========================================

Lipid metabolism disorder is one of the most important predisposing factors in fatty liver diseases pathogenesis, which is characterized by abnormal excessive lipid accumulation in the liver. Lipogenesis (lipid synthesis) and fatty acid β-oxidation (lipid utilization) are two major regulations that are responsible for this impaired hepatic lipid balance during fatty liver development. Recent studies demonstrated that SIRT1 plays a central beneficial role in controlling hepatic lipid metabolism as well as protects against high-fat diet or alcohol consumption induced hepatic steatosis primarily through regulating lipogenesis and fatty acid β-oxidation (Figure [1](#F1){ref-type="fig"}). We will describe them below.

Lipogenesis
-----------

Hepatic *de novo*lipogenesis is an important lipid source for TG deposition in the liver [@B3], [@B35]. Generally, there are two major transcriptional factors tightly controlling this TG synthesis process, which are insulin signaling responded SREBP-1c and glucose status associated ChREBP [@B3], [@B71]. Evidence has shown that both SREBP-1c and ChREBP are positive regulators for many lipogenic genes, including Acetyl-CoA carboxylase 1 (ACC1), fatty acid synthase (FAS) and so on [@B68]. SREBPs are DNA binding transcription factors that are critically involved in lipid synthesis regulation by binding to the promoter regions of its target lipogenic genes [@B72]. There are three isoforms of SREBPs: SREBP-1a, SREBP-1c, and SREBP-2 [@B73]. Among them, SREBP-1c is primarily expressed in the liver and is responsible for hepatic TG synthesis regulation [@B72]. After activated, SREBP-1c binds to and activates its downstream lipogenic genes, such as FAS, ACC1, stearoyl-CoA desaturase-1 (SCD1) to stimulate hepatic lipogenesis [@B74].

Recent studies revealed that SIRT1 down-regulates the transcriptional activity of SREBP-1c by deacetylating at Lys-289 and Lys-309 in the DNA binding domain of SREBP-1c, while acetylation at the same site by p300/CBP acetylase increases SREBP-1c transactivation [@B75]-[@B77]. Deacetylation of SREBP-1c by SIRT1 promotes the ubiquitination and proteasomal degradation [@B72], and decreases its stability and occupancy at the lipogenic genes [@B75]. Consistently, overexpression of SIRT1 in mice using adenovirus decreases acetylated SREBP-1c levels with suppressed SREBP-1c and lipogenic genes expression [@B75], whereas down-regulating SIRT1 by adenoviral siRNA or its inhibitors, nicotinamide and sirtinol, increases acetylation of SREBP-1c and its related lipogenic gene expression [@B75], [@B76]. Remarkably, SREBP-1c acetylation levels are significantly elevated in the fatty liver of high-fat diet induced obese mice, and adenovirus mediated overexpression of SIRT1 could attenuate this hepatic steatosis and related SREBP-1c mediated lipogenesis signaling [@B75]. Similarly, treatments with chemical activators of SIRT1, resveratrol and SRT1720, or NAD^+^precursor nicotinamide riboside also decrease SREBP-1c and related hepatic lipogenic gene and protein profiles, such as FAS, SCD1, and ACC1, thereby protecting liver against high-fat or high-fat plus high-sucrose diet induced hepatic steatosis [@B75], [@B78]-[@B80]. Consistent with the findings from NAFLD, SIRT1 also shows similar beneficial effect on alcohol-induced fatty liver diseases. Activation of SIRT1 by resveratrol abolishes ethanol-induced hyperacetylation of SREBP-1c and its increased transcriptional activity, and suppresses SREBP-1c mediated lipogenesis to alleviate alcoholic hepatic steatosis [@B81], [@B82]. Whereas hepatic SIRT1 deficiency in mice aggravates alcohol induced acetylated active nuclear form of SREBP-1 protein expression up-regulation and its regulated lipogenic enzymes mRNA expression, including FAS, SCD1 and ACC1, compared with alcohol treated control mice [@B29].

Besides SREBP-1c, ChREBP is another major transcription factor that involves in lipogenesis, which acts synergistically with SREBP-1c to fully stimulate TG synthesis [@B83]. Activation of ChREBP can be induced by high circulating glucose and fatty acids level through multiple post-transcriptional modifications, mostly phosphorylation and acetylation [@B84], and SIRT1 deficiency in mice could significantly elevate blood glucose and fatty acids level [@B68], [@B69]. It is reported that increased ChREBP acetylation is associated with both high-fat diet induced, and alcohol-induced hepatic steatosis, as well as increased ChREBP transcription activity and its target lipogenic genes expression [@B83], [@B85], [@B86], which is consistent with the suppression of SIRT1 expression and deacetylating activity in NAFLD and AFLD [@B81], [@B85]-[@B87]. Moreover, further direct evidence is provided from liver-specific SIRT1 knockout mice, which exhibits increased ChREBP expression associated with elevated acetylation of histone H3K9 and histone H4K16 on upstream of ChREBP promoter, and up-regulated ChREBP targeted lipogenic gene expression, FAS, ACC1 and elongase of long chain fatty acids family 6 (ELOVL6), consequently leads to hepatic steatosis under a normal feeding condition [@B68]. These data uncover an essential role of SIRT1 in regulating ChREBP related lipogenesis possibly through histone deacetylation on upstream of ChREBP promoter, thereby controlling lipid homeostasis in the liver.

Fatty acid β-oxidation
----------------------

Fatty acid β-oxidation is a major mean of TG utilization in liver, and PPARα/PGC-1α signaling pathway plays an essential role in regulating this process. PPARα is a ligand-activated transcription factor, and its primary endogenous ligands are fatty acids [@B88], [@B89]. Upon fatty acid binding, PPARα induces the expression of genes related to fatty acid catabolism in mitochondrial matrix [@B89]. PGC-1α is a transcriptional co-activator that interacts with PPARα to promote transcription of PPAR-α and, consequently, induces expression of fatty acid catabolic genes [@B28]. SIRT1 increases PPARα transcriptional activity primarily through its ability to deacetylate the co-activator PGC-1α to promote fatty acid β-oxidation in the liver [@B28], [@B90], [@B91]. It has been showed that liver-specific knockout SIRT1 or adenoviral-mediated liver-specific acute down-regulation of SIRT1 in mice causes PPARα transcriptional signal failure, which is associated with increased acetylation of PGC-1α and results in reduction of fatty acid β-oxidation as well as increased susceptibility of mice to high fat diet to induce hepatic steatosis [@B28]. Whereas overexpression of SIRT1 using adenovirus reduces PGC-1α acetylation level and ligand-dependent PPARα transcriptional signaling as well as the expression of PPARα/PGC-1α targeting genes, which leads to increased fatty acid β-oxidation and alleviation of fatty liver [@B28], [@B92]. Similar results were also obtained from high-fat or high-fat plus high-sucrose diet induced fatty liver mice treated with chemical SIRT1 agonists, SRT1720 and resveratrol, or NAD^+^precursor nicotinamide riboside [@B80], [@B93], [@B94]. Similarly to the action in response to high-fat diet, hepatic fatty acid β-oxidation is also impaired by alcohol intake through down-regulating the activity of SIRT1 and PGC-1α, as well as their targeting gene and protein expression [@B95], [@B96]. In ethanol fed liver-specific knockout mice, SIRT1 ablation further suppresses the mRNA expression levels of several PPARα/PGC-1α signaling enzymes involved in fatty acid β-oxidation [@B29]. Conversely, activating SIRT1 by resveratrol treatment reverses this effect associated with activation of PGC-1α, consequently alleviates alcoholic fatty liver in mice [@B82].

Collectively, these data indicate that SIRT1 acts as an essential regulator in hepatic lipid metabolism as summarized in figure [1](#F1){ref-type="fig"}, mainly through the control of SREBP-1c/ChREBP-dependent lipogenesis and PPARα/PGC-1α-dependent fatty acid β-oxidation, thereby inhibiting lipid synthesis and increasing lipid utilization respectively to benefit the fatty liver induced by high-fat diet and/or alcohol consumption. In addition to the direct regulation on lipid metabolism through SIRT1, study from our group on interaction between SIRT1 and SIRT6 reveals that SIRT1 also positively regulates SIRT6 gene expression by forming a complex together with FOXO3a and the nuclear respiratory factor 1 (NRF1) on the promoter of SIRT6, and SIRT6, in turn, deacetylates histone H3K9 of promoter of many genes involved in lipogenesis, fatty acid β-oxidation and glycolysis [@B23]. Our liver-specific SIRT6 knockout mice spontaneously develop fatty liver starting from 5-6 months age at a frequency of 43% (3/7), and reaches 90% (9/10) at 7.5-13 months of age [@B23], which uncovers an important role of SIRT1 in the regulation of lipid metabolism through SIRT6.

Role of SIRT1 in hepatic oxidative stress
=========================================

Hepatic oxidative stress is a well-established major contributor that is responsible for the pathogenesis of liver damage, specifically contributing to lipid peroxidation, mitochondrial dysfunction, and apoptosis in the liver [@B36]. The magnitude of oxidative stress is commonly based on imbalance levels between ROS production and antioxidant capacity [@B97]. Mitochondria are the most important cellular source of ROS [@B98], and mitochondria-derived ROS is generated through either mitochondrial respiration or the action of several oxidases, like NADPH oxidase [@B97]. On the other hand, the excessive ROS-induced oxidative stress can be detoxified by several antioxidant enzymes, including superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPX) [@B99]. Fork head box proteins (FOXO1, FOXO3, FOXO4) and PGC-1α are key transcription factors involved in redox regulation via activating the transcription of antioxidant enzyme genes to increase ROS-detoxifying capacity [@B100], [@B101]. It has been reported that SIRT1 has a regulatory effect on oxidative stress through deacetylating of FOXOs and PGC-1α to increase their transcriptional activity on antioxidant enzyme genes [@B90], [@B102]-[@B105]. In NAFLD induced by high-fat diet, activation of SIRT1 with either NAD^+^precursor nicotinamide riboside or SRT1720 could deacetylate and activate FOXO1 and PGC-1α transcriptional activity, then lead to higher expression of target antioxidant genes, subsequently protect against hepatic oxidative stress in fatty liver [@B93], [@B106]. Consistently, in another study of high-carbohydrate induced fatty liver diseases, resveratrol treatment significantly increases antioxidant enzymes including SOD, CAT and GPX, and reduces pro-oxidant - nitric oxide synthase and lipid peroxidation product - malondialdehyde (MDA), thus exhibits anti-oxidative stress effect in fatty liver [@B107]. Similar results can also be found in alcoholic fatty liver diseases where activation of SIRT1 deacetylase activity by resveratrol enhances PGC-1α transcriptional activity and attenuates oxidative stress as judged by decreasing MDA levels [@B82]. Furthermore, genetic models in which SIRT1 expression level is modulated also provide more direct supports for the regulatory role of SIRT1 on oxidative stress. In transgenic mice, SIRT1-overexpression increases the expression of antioxidant protein manganese-dependent superoxide dismutase (MnSOD) and NRF1, a crucial regulator protecting from ROS, which protect the mice from high-fat induced hepatic oxidative stress and fatty liver [@B30]. Conversely, hepatic SIRT1 deletion significantly increases ROS levels in the liver as well as in multiple other tissues, consequently leading to severe hepatic oxidative stress and eventually fatty liver diseases [@B29], [@B68], [@B69].

In summary, SIRT1 supports a beneficial effect on hepatic oxidative stress as well as associated fatty liver diseases, and this protective action is possibly through stimulation of FOXOs and PGC-1α (Figure [2](#F2){ref-type="fig"}). However, proofs for critical regulation of SIRT1 on oxidative stress, especially how SIRT1 directly regulates FOXOs and PGC-1α and their downstream antioxidant genes in fatty liver diseases still need further investigation.

Role of SIRT1 in hepatic inflammation
=====================================

Growing evidences link inflammation to the initiation of liver injury and the progression of hepatic steatosis to steatohepatitis, which are characterized by presence of macrophage infiltration and high levels of pro-inflammatory cytokines [@B4], [@B46]-[@B48]. The transcription factor nuclear factor-κB (NF-κB) and its signaling pathway play central roles in this inflammation process [@B108]. NF-κB forms as a heterodimeric protein complex containing a DNA-binding component and a transactivation domain [@B109]. The most ubiquitous NF-κB dimer is RelA/p65 heterodimer that held in the cytoplasm complexed with its inhibitory protein IκB [@B110]. Once inflammatory response is triggered, IκB becomes phosphorylated by the IκB kinase and targeted for its ubiquitination and degradation [@B101]. Following IκB degradation, NF-κB is able to be released from IκB and translocate into nucleus to mediate p300/CBP recruitment, while acetylating RelA/p65 by p300/CBP activates NF-κB transcription, consequently enhances downstream genes involved in pro-inflammation [@B109], [@B111]. It has been showed that SIRT1 interacts with RelA/p65, a sub-unit of NF-κB and inhibits its transcriptional activity by deacetylating RelA/p65 at lysine 310 [@B112], [@B113].

More and more evidences indicate that SIRT1 incorporates in the pathogenesis of inflammation associated fatty liver diseases. It is reported that liver-specific knockout SIRT1 or whole-body SIRT1 heterozygous knockout could significantly increase macrophage accumulation and infiltration accompanied with higher levels of macrophage markers expression in the liver, such as macrophage inflammatory proteins 1 α (MIP1α), F4/80 and CD11β, in response to high-fat diet challenge [@B27], [@B28]. Meanwhile, several pro-inflammatory cytokines (i.e. IL-1, IL-6 and TNF-α) are also induced in these SIRT1 deficient mouse models [@B27], [@B28]. Consequently, the deletion of SIRT1 exacerbates the development of hepatic inflammation and fatty liver diseases when challenged with high-fat diet or even mediate-fat diet [@B27], [@B28]. Consistent with these observations, myeloid cell-specific disruption of SIRT1 in mice reveals that SIRT1 deficiency in macrophages induces NF-κB hyperacetylation and increases NF-κB transcriptional activation in the liver, resulting in hepatic inflammation [@B114] and hepatic steatosis upon high-fat diet [@B115], whereas overexpression of SIRT1 in transgenic mice shows beneficial effects on fatty liver induced by high-fat diet and lower activation of pro-inflammatory cytokines, such as IL-6 and TNF-α, via down-regulation of NF-κB activity [@B30]. These results are consistent to those with activation of SIRT1 by resveratrol or nicotinamide riboside treatment under high-fat or high-fat plus high-sucrose diet conditions [@B78], [@B80], [@B87], [@B107], [@B116]. Similarly, SIRT1 agonist, resveratrol, also exhibits anti-inflammation effects in ethanol metabolite-treated macrophages via down-regulating NF-κB transcriptional activity and TNF-α production [@B113]. In addition to local inflammation in the liver, adipose tissue-derived inflammation and its pro-inflammatory cytokines release into circulation are also important causes contributing to pathogenesis of fatty liver diseases, especially hepatic inflammation. Several studies demonstrate that SIRT1 also play a crucial role in the regulation of adipose tissue inflammation in response to high-fat induced fatty liver diseases [@B27], [@B114], [@B115]. From the analyses of all these SIRT1 mutant mice, it is clear that the SIRT1 deficiency induces macrophage infiltration and inflammatory cytokines release through NF-κB transcriptional activity up-regulation in adipose tissue, subsequently results in increased adipose tissue inflammation as well as hepatic inflammation [@B27], [@B114], [@B115], [@B117], whereas genetic overexpression of SIRT1 prevents adipose tissue macrophage infiltration and inflammation induced by high-fat feeding [@B117].

These data indicate that SIRT1 is an essential negative inflammatory regulator in high-fat diet or alcohol induced fatty liver diseases, mainly through deacetylating NF-κB and down-modulating NF-κB transcriptional activity, thereby reducing macrophage infiltration and pro-inflammatory cytokines production in the liver as well as in the adipose tissue (Figure [2](#F2){ref-type="fig"}).

SIRT1 as a therapeutic target for fatty liver diseases
======================================================

Increasing attentions have been paid to the therapy of fatty liver diseases, as its prevalence is increasing dramatically in recent years. Meanwhile, it is getting clear that fatty liver diseases are also commonly associated with many other metabolic complications, such as insulin resistance, hyperlipidemia, consequently increase the high risk of obesity and type 2 diabetes mellitus [@B3]. However, there are no specific and effective medicinal therapies for alcoholic or non-alcoholic fatty liver diseases, except restricting patients with less-alcohol consumption, low-fat/low-calorie diet intake and more physical exercise. Thus, the demand of identifying new therapeutic targets for fatty liver diseases and developing corresponding agents is necessary and urgent.

Because SIRT1 plays essential and beneficial roles in various metabolic pathways involved in fatty liver and other metabolic disorders [@B6], [@B22], [@B27]-[@B32], [@B118], many studies have tested if pharmacological activation of SIRT1 could serve as an effective therapeutic approach for preventing the development of fatty liver diseases at all stages, including the onset, progression and complication, as summarized in table [2](#T2){ref-type="table"}. Shortly after the natural polyphenolic compound resveratrol was identified as direct SIRT1 activator for the first time [@B119], extensive *in vivo* studies in mammal models have been investigated on its protective functions against fatty liver diseases. From these studies, resveratrol exhibits a wide spectrum of beneficial effects involved in controlling lipid metabolism, oxidative stress and inflammation to ameliorate fatty liver diseases [@B33], [@B78], [@B79], [@B82], [@B87], [@B107], [@B116], [@B120], [@B121]. In addition to resveratrol, a few other natural polyphenols also present similar beneficial effects through SIRT1 activation [@B122]-[@B128]. However, natural polyphenols are not specific and potent to activate SIRT1 in mammals [@B129]-[@B131], several new SIRT1 agonists with higher specificity and potency are developed, like SRT1720 discovered by Sirtris Pharmaceuticals [@B132], and show great protective effect against NAFLD [@B93], [@B133], [@B134]. Of note, some existing approved drugs also elicit promising therapeutic effects on fatty liver diseases through activation SIRT1 and a number of other signaling molecules, for example, Olaparib, a Poly (ADP-ribose) polymerase (PARP) inhibitor. The protective effects of Olaparib and other PAPR inhibitors against NAFLD and AFLD have been intensively reported during recent several months [@B135]-[@B138]. Through restoring NAD^+^levels and increasing the activity of SIRT1, but not the activity of SIRT2 and SIRT3 [@B139], PARP inhibition reduces steatosis formation, oxidative stress and inflammation in the liver and prevents steatohepatitis and fibrosis progression in a SIRT1-dependet manner [@B135]-[@B138]. Given that PARP inhibitors are already FDA-approved drugs for other diseases, such as cancer, these agents possess the promising potential to be repurposed for use in the fatty liver diseases.

With the confidence obtained from animal studies, multiple human clinical trials have being conducted to explore the pharmacological potential of resveratrol to treat fatty liver and various human metabolic diseases (Table [3](#T3){ref-type="table"}), and at least two of them have been advanced to phase IV clinical trial for treating gestational diabetes (NCT01997762) and polycystic ovary syndrome (PCOS) with insulin resistance (NCT02766803). Of note, five of these human trials on resveratrol are specifically targeted for fatty liver diseases treatment (NCT02216552, NCT02030977, NCT01446276, NCT01635114 and NCT01464801), and two of them are currently at phase III clinical trial stage. But to our great surprise, the clinical trial case reports on the effect of resveratrol against fatty liver diseases from four independent groups are inconsistent, two groups claimed that 3-month resveratrol treatment could significantly reduce alanine aminotransferase (ALT), hepatic steatosis and inflammation compared with placebo group, which indicates the good beneficial effect of resveratrol against fatty liver diseases [@B140]-[@B142]. One another group reported that resveratrol treated patients only showed a non-significant plasma ALT alleviation (*p*=0.51) and a limited hepatic lipid content reduction (3.8% decrease, *p*=0.38), but some serious adverse events were observed in 2 out of 14 patients during 6 months treatment [@B143]. On the contrary, according to the study from the fourth group, there were no beneficial effect of resveratrol on all the parameters that they examined related to liver injury, hepatic steatosis, insulin sensitivity and inflammation in NAFLD patients, instead, significantly increased hepatic stress was observed in patients under 6-month resveratrol administration [@B144]. These clinical trial results leave us a puzzling understanding on resveratrol effect requiring more examinations at clinical trial level to confirm it. In addition to the extensive effort on developing resveratrol to a clinically available drug for metabolic diseases treatment, two companies (Royal DSM Nutritional Products, Inc., Amsterdam, Netherlands and Resveratrol Partners LLC, Las Vegas, US) also applied an alternative way bringing resveratrol to be commercially available by reforming resveratrol to market-acceptable products, resVida® and Longevinex® respectively, as dietary and food ingredient for people with metabolic burdens to ameliorate their physical conditions.

Conclusions and future aspects
==============================

We have reviewed the latest advances on the roles of SIRT1 in maintaining normal liver development and functioning, as well as the beneficial effects of SIRT1 activation against fatty liver diseases by its activators. As summarized in figure [1](#F1){ref-type="fig"} & [2](#F2){ref-type="fig"}, SIRT1 plays important roles in regulating lipid metabolism, hepatic oxidative stress and inflammation in the liver. Activation of SIRT1 inhibits hepatic *de novo*lipogenesis by deacetylating SREBP-1c and ChREBP (Figure [1](#F1){ref-type="fig"}), increases fatty acid β-oxidation via deacetylating PPARα/PGC-1α (Figure [1](#F1){ref-type="fig"}), defends hepatic oxidative stress through enhancing antioxidant capability via deacetylating FOXOs and PGC-1α (Figure [2](#F2){ref-type="fig"}), and reduces local and circulating inflammation through deacetylating NF-κB in liver and adipose tissue (Figure [2](#F2){ref-type="fig"}). Based on evidences obtained from fatty liver mice treated with SIRT1 activators (Table [2](#T2){ref-type="table"}) and from human clinical trials on SIRT1 activators against metabolic disorders, including fatty liver diseases (Table [3](#T3){ref-type="table"}), activation of SIRT1 and its downstream signaling is very likely to serve as promising therapeutic approaches for the treatment of fatty liver diseases.

Although representative SIRT1 activators, like resveratrol and SRT501 (micronized resveratrol formulation developed by Sirtris Pharmaceuticals), are very promising for fatty liver diseases treatment and have been advanced to phase IV clinical trials for metabolic diseases, there are still some unsolvable limitations for them as clinical drugs, including inconsistent beneficial effects varying from independent trials [@B140]-[@B144], off-target problem caused by non-specific activation [@B129], serious side effect after long-term prescription (6 month) [@B143], [@B144], and significant poor bioavailability with rapid metabolism [@B130], [@B131]. Thus, further investigation on finding new SIRT1 activators with better safety and improved bioavailability is needed. In recent years, a series of potent SIRT1 agonists have been discovered from large-scale screening, and some of them are undergoing phase I & II clinical trials, including SRT2104, SRT2379 and SRT3025 (Table [3](#T3){ref-type="table"}). However, cautious evaluation on these newly developed SIRT1 agonists are still necessary to avoid any un-wanted side effects, especially for those later developed ones with 800-1000-fold more potency than resveratrol in activating SIRT1 [@B132]. Thus, for pharmacological application of SIRT1 activators, there are still a lot of emerging works to do, so as to ultimately utilize SIRT1 as a useful therapeutic target in fatty liver diseases and other metabolic diseases.

In addition to pharmacological concerns on SIRT1 activators, more extensive studies on diverse roles of SIRT1 activation in multi-organ level are also highly needed, such as in adipose tissue-liver axis. During fatty liver formation, fatty acid flux from adipose tissue to liver has been demonstrated as an important out-coming lipid source both in NAFLD and AFLD (Figure [2](#F2){ref-type="fig"}) [@B35], [@B40], [@B42]. As summarized in figure [2](#F2){ref-type="fig"}, SIRT1 activation promotes lipolysis in adipocytes and releases large amount of free fatty acids to circulation [@B145]-[@B147] which may induce or aggravate hepatic steatosis formation. So, it is risky to apply SIRT1 activating drugs for fatty liver diseases treatment without organ specificity, which might explain why inconsistent results occurred in several fatty liver diseases related clinical trials with resveratrol treatment [@B140]-[@B144]. In order to apply SIRT1 as a reliable therapeutic target for fatty liver and other metabolic diseases, we need to further extensively illuminate the diverse roles of SIRT1 in multi-organ level, especially in fatty liver diseases related adipose tissue-liver axis and pancreas-liver axis.

Since fatty liver diseases always encompass a continued spectrum of liver damages that might advance to liver cancer in some cases, future efforts will also be delivered toward the interplays among SIRT1, fatty liver and cancer. It is noteworthy to indicate that the roles of SIRT1 in liver cancer are controversial. In some reports, SIRT1 protein expression was significantly overexpressed as compared with adjacent non-tumor liver tissues, and the elevated SIRT1 levels are correlated with cancer grades and predicted poor prognosis [@B148]-[@B150]. However, in other reports it was also shown that 2-fold reduction of SIRT1 protein levels were displayed in 46 of 263 hepatocellular carcinoma tumors when compared to their normal controls [@B151] and activation of SIRT1 resulted in antitumor effect in liver cancer [@B152]-[@B155]. As the controversy over whether SIRT1 is a tumor suppressor or oncogene remains unsolved [@B8], it needs to be cautious on fatty liver patients with cancer complications when treating with SIRT1 activators, and to be paid more effort on elucidating SIRT1 roles among different degrees of liver diseases (e.g. fatty liver and liver cancer) and different types of diseases.
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![Fatty liver diseases are initiated by aberrant hepatic lipid metabolism, and sirtuin 1 (SIRT1) activation plays beneficial effect against the process through inhibiting *de novo* lipogenesis and increasing fatty acid β-oxidation. Liver steatosis is the initial stage of fatty liver diseases, which is characterized by excessive triglyceride (TG) deposition as lipid droplets in the liver. Lipid metabolism is tightly linked with dietary fat, calorie and alcohol intake, which could be subsequently digested and convert to circulating TG-rich chylomicrons, free fatty acid (FFA), glucose, insulin and so on. Circulating TG-rich chylomicrons and free fatty acid (FFA) could be uptaken by liver through transmembrane proteins. High levels of circulating glucose and insulin could stimulate *de novo* lipogenesis activating transcription factors carbohydrate response element binding protein (ChREBP) and sterol regulatory element binding protein-1c (SREBP-1c), followed by activating their downstream lipogenic enzymes including fatty acid synthase (FAS), acetyl-CoA carboxylase 1 (ACC1), stearoyl-CoA desaturase-1 (SCD1) and elongase of long chain fatty acids family 6 (ELOVL6) to synthesize FFA and TG in the liver. In order to maintain lipid homeostasis, there are also two removal pathways for acquired FFA and TG, including metabolizing FFA through fatty acid β-oxidation in mitochondria via peroxisome proliferator-activated receptor alpha (PPARα) / peroxisome proliferator-activated receptor-gamma co-activator 1 alpha (PGC-1α) signaling, and secreting TG into blood circulation as the form of very low-density lipoprotein (VLDL). Under high-fat diet, high-calorie diet and/or heavy alcohol intake condition, excessive lipid acquisition usually is stimulated through increasing lipid uptake and/or lipogenesis, meanwhile lipid removal pathway could also be impaired by decreasing fatty acid β-oxidation and/or VLDL secretion. Together, the imbalance of hepatic TG/fatty acids flux acquisition and removal consequently cause steatosis in the liver. During the process, SIRT1 activation shows beneficial effect through inhibiting lipogenesis by deacetylating SREBP-1c and ChREBP to block their downstream lipogenic genes, and increasing fatty acid β-oxidation via deacetylating PPARα/PGC-1α, thus rebalances the hepatic lipid hemostasis.](ijbsv13p0852g001){#F1}

![Accumulated hepatic oxidative stress and inflammation promote fatty liver diseases progression, and SIRT1 activation plays beneficial effect against diseases progression. Accumulated lipid droplets in the liver will trigger further hepatic oxidative and inflammation, which subsequently develop a continued liver damage process. The excessive hepatic oxidative stress and inflammation are characterized by abundant reactive oxygen species (ROS) production and large cytokine production, particularly tumor necrosis factor α (TNF-α) and interleukin 6 (IL-6). Additionally, adipose tissue also contributes to the diseases aggravation by secreting FFA and inflammatory cytokines to circulation, which further could be delivered to liver. During fatty liver diseases progression, SIRT1 activation plays beneficial roles on defending hepatic oxidative stress through enhancing antioxidant capability involving fork head box proteins (FOXOs) and PGC-1α deacetylation, and reducing pro-inflammatory cytokines production through deacetylating nuclear factor-κB (NF-κB) both in the liver and in the adipose tissue. In addition to beneficial effect, SIRT1 activation also possesses a contradictory role in adipose tissue-liver axis, which might exacerbate fatty liver formation. Under SIRT1 activation, transcriptional activity of peroxisome proliferator-activated receptor gamma (PPARγ) is repressed and FOXO1/ adipose triglyceride lipase (ATGL) signaling is activated, which promote lipolysis of adipose tissue to increase large amount of FFA fluxing to circulation, later might be uptaken by liver.](ijbsv13p0852g002){#F2}

![SIRT1 liver-specific knockout causes liver steatosis. (A) Summary of fatty liver cases at different age among control (Sirt1^flox5-6^) and liver-specific SIRT1 knockout (Sirt1^LKO^) male mice. (B) Oil Red O staining of 14 months old male liver with higher magnification. (C-E) Liver TG content (C), plasma FFA amount (D) and plasma TG content (E) of 9 months old male mice (n=11). \**p*\<0.05. (Adapted from Wang *et al.* 2010 [@B68])](ijbsv13p0852g003){#F3}

###### 

Lessons from genetic mouse models on SIRT1 related to fatty liver diseases

       Modification of SIRT1                           Diet                              Main metabolic phenotypes related to fatty liver diseases                                                                                                     Targets for SIRT1        Involved mechanisms               Ref.
  ---- ----------------------------------------------- --------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------ --------------------------------- ---------
  1    SIRT1 heterozygous mice (exon 4)                Mediate-fat diet; High-fat diet   SIRT1 deficiency mice show more hepatic lipid accumulation and inflammatory cytokines production than control mice                                            SREBP-1c                 ↑Lipogenesis; ↑Inflammation       \[27\]
  2    Liver-specific SIRT1 knockout mice (exon 5-6)   Standard diet                     SIRT1 deficiency mice show more hepatic lipid accumulation than control mice                                                                                  ChREBP                   ↑Lipogenesis                      \[68\]
  3    Liver-specific SIRT1 knockout mice (exon 5-6)   Standard diet                     SIRT1 deficiency mice show more ROS production, hyperglycemia and insulin resistance than control mice                                                        Rictor                   ↑Oxidative stress                 \[69\]
  4    Liver-specific SIRT1 knockout mice (exon 4)     High-fat diet                     SIRT1 deficiency mice show more hepatic lipid accumulation and inflammatory cytokines production than control mice                                            PPARα/PGC-1α             ↓FA β-oxidation                   \[28\]
  5    Liver-specific SIRT1 knockout mice (exon 4)     Alcoholic diet                    SIRT1 deficiency mice show more liver injury and liver fibrosis than control mice                                                                             PDGFR-α                  ↑Inflammation                     \[59\]
  6    Liver-specific SIRT1 knockout mice (exon 4)     Alcoholic diet                    SIRT1 deficiency mice show more hepatic lipid accumulation and inflammatory cytokines production than control mice                                            Lipin-1                  ↑Inflammation                     \[29\]
  7    Liver-specific SIRT1 knockout mice (exon 4)     Prolonged fasting                 SIRT1 deficiency mice show more hepatic lipid accumulation than control mice                                                                                  PPARα/FGF21              ↓FA β-oxidation                   \[134\]
  8    Liver-specific SIRT1 knockout mice (exon 4)     High-fat diet                     SIRT1 deficiency mice show less hepatic lipid accumulation than control mice (inconsistent with other studies)                                                SREBP-1c                 ↓Lipogenesis                      \[67\]
  9    Liver-specific SIRT1 knockdown mice             Standard diet                     SIRT1 deficiency mice show more hepatic lipid accumulation and hyperglycemia than control mice                                                                PGC-1α; SREBP-1c         ↑Lipogenesis                      \[92\]
  10   Fat-specific SIRT1 knockout mice                High-fat diet                     SIRT1 deficiency mice show more adipose macrophage infiltration and inflammatory cytokines production than control mice                                       NF-κB                    ↑Inflammation                     \[117\]
  11   Fat-specific SIRT1 knockout mice (exon 4)       High-fat diet                     SIRT1 deficiency mice show increased or reduced inflammation in adipose tissue on short-term or chronic high-fat diet respectively compared to control mice   PPARγ                    ↑Inflammation or ↓Inflammation    \[156\]
  12   Myeloid-specific SIRT1 knockout mice (exon 4)   High-fat diet                     SIRT1 deficiency mice show more inflammatory cytokines production than control mice                                                                           NF-κB                    ↑Inflammation                     \[115\]
  13   Myeloid-specific SIRT1 knockout mice (exon 4)   High-fat diet                     SIRT1 deficiency mice show more hepatic lipid accumulation, peroxides production and macrophage infiltration than control mice                                NF-κB                    ↑Inflammation                     \[114\]
  14   Myeloid-specific SIRT1 knockout mice (exon 4)   High-fat diet                     SIRT1 deficiency mice show more hepatic macrophage infiltration and inflammatory cytokines production than control mice than control mice                     NF-κB                    ↑Inflammation                     \[157\]
  15   Myeloid-specific SIRT1 knockout mice (exon 4)   High-fat diet                     SIRT1 deficiency mice show more hepatic lipid accumulation and inflammatory cytokines production than control mice                                            NF-κB; SREBP-1c          ↑Inflammation; ↑Lipogenesis       \[158\]
  16   Fat-specific SIRT1 overexpressing mice          Standard diet                     SIRT1 overexpressing mice show increased adipose tissue lipolysis compared to control mice                                                                    ACC1                     ↑Lipolysis                        \[147\]
  17   SIRT1 overexpressing mice                       Alcoholic diet                    SIRT1 overexpressing mice show less liver injury and liver fibrosis than control mice                                                                         PDGFR- α                 ↓Inflammation                     \[59\]
  18   SIRT1 overexpressing mice                       High-fat diet                     SIRT1 overexpressing mice show less hepatic lipid accumulation and inflammatory cytokines production than control mice                                        SREBP-1c; MnSOD; NF-κB   ↓Oxidative stress ↓Inflammation   \[30\]
  19   SIRT1 overexpressing mice                       High-fat diet                     SIRT1 overexpressing mice show less adipose macrophage infiltration than control mice                                                                         NF-κB                    ↓Inflammation                     \[117\]

###### 

Summary of pharmacological studies about identified SIRT1 activators and other potential chemical agents in animal models of fatty liver diseases

       Chemical agents                        Models   Possible targets                             Involved mechanisms                                 Ref.
  ---- -------------------------------------- -------- -------------------------------------------- --------------------------------------------------- ---------
  1    Resveratrol                            NAFLD    SIRT1-PPAR-γ/PPAR-α                          ↓Lipogenesis; ↑FA β-oxidation                       \[33\]
  2    Resveratrol                            NAFLD    SIRT1-AMPK/SREBP-1c                          ↓Lipogenesis                                        \[120\]
  3    Resveratrol                            NAFLD    SIRT1-AMPK/PGC-1α/SREBP-1c                   ↓Lipogenesis; ↑FA β-oxidation                       \[79\]
  4    Resveratrol                            NAFLD    SIRT1-SREBP-1c/NF-κB                         ↓Lipogenesis; ↓Inflammation                         \[78\]
  5    Resveratrol                            NAFLD    SIRT1-AMPK/ NF-κB                            ↓Inflammation                                       \[116\]
  6    Resveratrol                            NAFLD    \-                                           ↓Oxidative stress                                   \[107\]
  7    Resveratrol                            NAFLD    \-                                           ↓Inflammation                                       \[87\]
  8    Resveratrol                            NAFLD    SIRT1- PPARα-FGF21                           ↑FA β-oxidation                                     \[134\]
  9    Resveratrol                            NAFLD    SIRT1-LXRα                                   ↓Lipogenesis                                        \[121\]
  10   Resveratrol                            AFLD     SIRT1-AMPK/PGC-1α/SREBP-1c                   ↓Lipogenesis; ↑FA β-oxidation                       \[82\]
  11   Resveratrol                            AFLD     SIRT1-AMPK                                   ↓Lipogenesis                                        \[159\]
  12   SRT1720                                NAFLD    SIRT1-PGC-1α/SREBP-1c                        ↓Lipogenesis; ↓Inflammation                         \[133\]
  13   SRT1720                                NAFLD    SIRT1-AMPK/PGC-1α/PPARα/FOXO1                ↑FA β-oxidation; ↓Oxidative stress                  \[93\]
  14   SRT1720                                NAFLD    SIRT1- PPARα-FGF21                           ↑FA β-oxidation                                     \[134\]
  15   α -Lipoic acid                         NAFLD    SIRT1-LKB1/AMPK/SREBP-1c/FOXO1/Nrf2          ↓Lipogenesis; ↓Oxidative Stress                     \[160\]
  16   α-Lipoic acid                          NAFLD    SIRT1-AMPK/LKB1                              ↓Lipogenesis; ↑FA β-oxidation                       \[161\]
  17   α‑Mangostin                            NAFLD    SIRT1-AMPK/ PPAR-γ                           \-                                                  \[122\]
  18   Apo-10\'-Lycopenoic Acid               NAFLD    SIRT1-FOXO1                                  \-                                                  \[162\]
  19   Cardiotrophin-1                        NAFLD    SIRT1-AMPK/LKB1/SREBP-1c/PGC-1α              ↓Lipogenesis; ↑FA β-oxidation                       \[163\]
  20   Carnosic acid                          NAFLD    SIRT1-p66shc                                 ↓Oxidative stress                                   \[123\]
  21   Carvacrol                              NAFLD    SIRT1-AMPK/SREBP-1c                          ↓Lipogenesis; ↓Inflammation                         \[124\]
  22   Cobalt protoporphyrin                  NAFLD    HO-1- SIRT1-SREBP-1c                         ↓Lipogenesis; ↓Oxidative stress; ↓Inflammation      \[164\]
  23   Cobalt protoporphyrin                  NAFLD    HO-1- SIRT1-PPARα/AMPK                       ↓Lipogenesis; ↓Oxidative stress; ↓Inflammation      \[165\]
  24   Epigallocatechin-3-gallate             NAFLD    SIRT1-AMPK/LKB-SREBP-1c/ChREBP               ↓Lipogenesis;                                       \[125\]
  25   Exendin-4                              NAFLD    SIRT1-AMPK/LKB1/SREBP-1c/FOXO1               ↓Lipogenesis; ↑FA β-oxidation                       \[166\]
  26   Exendin-4                              NAFLD    SIRT1-FGF21                                  ↑FA β-oxidation                                     \[167\]
  27   Indole-3-carbinol                      NAFLD    SIRT1-AMPK/SREBP-1c                          ↓Lipogenesis; ↓ Inflammation                        \[168\]
  28   Leucine                                NAFLD    SIRT1-PGC-1α/FOXO1                           ↑FA β-oxidation                                     \[34\]
  29   Lipoic acid                            NAFLD    SIRT1-PGC-1α/FOXO3α                          ↓Oxidative stress                                   \[169\]
  30   Methylene blue                         NAFLD    SIRT1-PGC-1α/PPARα/AMPK/SREBP-1c             ↓Lipogenesis                                        \[170\]
  31   N1-methylnicotinamide                  NAFLD    SIRT1-FOXO1                                  ↓Lipogenesis; ↓Inflammation                         \[171\]
  32   Nicotinamide riboside                  NAFLD    SIRT1-FOXO1                                  ↓Oxidative stress                                   \[106\]
  33   Nicotinamide riboside                  NAFLD    SIRT1-NLRP3                                  ↓Inflammation                                       \[172\]
  34   Nicotinamide riboside                  NAFLD    SIRT1-PPAR-γ/ SREBP-1c/ PPARα/ PGC-1α/Nrf1   ↓Lipogenesis; ↑FA β-oxidation; ↓Inflammation        \[80\]
  35   Olaparib (PARP inhibitor)              NAFLD    SIRT1-SREBP-1c/ PPARα                        ↓Lipogenesis; ↓Oxidative stress; ↓Inflammation      \[135\]
  36   Olaparib (PARP inhibitor)              NAFLD    \-                                           ↑FA β-oxidation; ↓Oxidative stress; ↓Inflammation   \[136\]
  37   Pifithrin-α ρ-nitro                    NAFLD    SIRT1-PGC-1α/PPARα; SIRT1-LKB1/AMPK          ↑FA β-oxidation                                     \[173\]
  38   Salvianolic acid B                     NAFLD    SIRT1-HMGB1-NF-κB/TLR4                       ↓Inflammation                                       \[126\]
  39   (S)YS-51                               NAFLD    SIRT1-AMPK/LKB1/SREBP-1c                     ↓Lipogenesis; ↓Inflammation                         \[174\]
  40   Quercetin                              NAFLD    SIRT1-NF-κB                                  ↓Inflammation                                       \[128\]
  41   PJ-34 (PARP inhibitor)                 NAFLD    SIRT1- PPARα                                 ↑FA β-oxidation                                     \[137\]
  42   Troxerutin                             NAFLD    SIRT1-AMPK                                   ↓Lipogenesis; ↑FA β-oxidation; ↓Oxidative Stress    \[175\]
  43   14-Deoxyandrographolide                AFLD     SIRT1-AMPK/SREBP-1c                          ↓Lipogenesis                                        \[176\]
  44   5-Aminoisoquinoline (PARP inhibitor)   AFLD     SIRT1-SREBP-1c/ PGC-1α/ FOXO1                ↓Lipogenesis; ↓Oxidative stress; ↓Inflammation      \[135\]
  45   Demethyleneberberine                   AFLD     SIRT1-AMPK-PGC-1α                            ↑FA β-oxidation                                     \[177\]
  46   Salvianolic acid B                     AFLD     SIRT1-ChREBP                                 ↓Lipogenesis; ↓Inflammation                         \[127\]
  47   Olaparib (PARP inhibitor)              AFLD     SIRT1- PGC-1α/ FOXO1                         ↓Lipogenesis; ↓Oxidative stress; ↓Inflammation      \[135\]
  48   PJ-34 (PARP inhibitor)                 AFLD     SIRT1- PPARα/ NF-κB                          ↓Lipogenesis; ↑FA β-oxidation; ↓Inflammation        \[138\]
  49   PJ-34 (PARP inhibitor)                 AFLD     SIRT1-SREBP-1c/ PGC-1α/ FOXO1                ↓Lipogenesis; ↓Oxidative stress; ↓Inflammation      \[135\]
  50   Rosiglitazone                          AFLD     SIRT1-AMPK/PGC-1α/FOXO1                      ↓Lipogenesis; ↑FA β-oxidation                       \[178\]

###### 

Summary of clinical trials on SIRT1 activators for fatty liver diseases and other metabolic diseases.

                                                                                              Study description                                                                                                                                  Phase      Identifier    Drugs                 Diseases or Conditions                Status                   Study period             
  ------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------- ---------- ------------- --------------------- ------------------------------------- ------------------------ --------------------- -- --
  Studies on fatty liver diseases                                                                                                                                                                                                                                                                                                                                                       
  1                                                                                           The effects of resveratrol on lipid profiles, liver enzymes, inflammatory factors and hepatic fibrosis in nonalcoholic steatohepatitis patients    II & III   NCT02030977   Resveratrol           NAFLD                                 Completed                Jun. 2012-Mar. 2013      
  2                                                                                           Safety and efficacy of resveratrol for the treatment of NAFLD and associated insulin resistance in overweight and obese adolescents                II & III   NCT02216552   Resveratrol           NAFLD; Obesity                        Recruiting               Aug. 2015-               
  3                                                                                           Resveratrol in patients with non-alcoholic fatty liver disease                                                                                     \-         NCT01464801   Resveratrol           NAFLD                                 Completed                Sep.2011-Jun. 2015       
  4                                                                                           Evaluate the effects of resveratrol on liver fat content, body fat distribution and insulin sensitivity                                            \-         NCT01635114   Resveratrol           NAFLD; Insulin resistance             Completed                Jun. 2012-Sep. 2015      
  5                                                                                           Long-term investigation of resveratrol on lipid turnover in obese men with NAFLD                                                                   \-         NCT01446276   Resveratrol           NAFLD; Obesity                        Completed                Nov.2011-Apr. 2014       
  Studies on metabolic diseases (disorders) associated inflammation and/or oxidative stress                                                                                                                                                                                                                                                                                             
  6                                                                                           Effects of resveratrol on inflammation and oxidative stress of non-dialysis chronic kidney diseases patients                                       III        NCT02433925   Resveratrol           Chronic renal insufficiency           Completed                Jan. 2013-Dec. 2014      
  7                                                                                           Anti-inflammatory and antioxidant effects of resveratrol on healthy adults                                                                         III        NCT01492114   Resveratrol           Healthy volunteer                     Completed                Jul. 2011-Mar. 2012      
  8                                                                                           Effects of resveratrol on inflammation in type 2 diabetic patients                                                                                 III        NCT02244879   Resveratrol           Type 2 diabetes                       Completed                Oct 2013-Feb. 2016       
  9                                                                                           Effect of resveratrol on insulin resistance and inflammatory mediators in obese and type 2 diabetic subjects                                       II & III   NCT01158417   Resveratrol           Type 2 diabetes; Obesity              Unknown                  Dec. 2008-               
  10                                                                                          Effect of resveratrol on age-related insulin resistance and inflammation in humans                                                                 II         NCT01354977   Resveratrol           Type 2 diabetes; Insulin resistance   Unknown                  Mar. 2008-               
  11                                                                                          The effects of trans-resveratrol on insulin resistance, inflammation, and the metabolic syndrome                                                   II         NCT01714102   Resveratrol           Obesity; Insulin resistance           Active, not recruiting   Oct. 2012-               
  12                                                                                          A phase I dose-ranging study to evaluate the activity of SRT2379 on endotoxin induced inflammatory response in healthy male subjects               I          NCT01416376   SRT2379               Healthy volunteer treated with LPS    Completed                Aug. 2011-Dec. 2011      
  13                                                                                          A phase I study to evaluate a single oral dose of SRT2379 on the endotoxin induced inflammatory response in healthy male subjects                  I          NCT01262911   SRT2379               Healthy volunteer treated with LPS    Completed                Feb. 2011-Apr. 2011      
  14                                                                                          A phase I study to evaluate multiple oral doses of SRT2104 on the endotoxin induced inflammatory response in healthy male subjects                 I          NCT01014117   SRT2104               Healthy volunteer treated with LPS    Completed                Dec. 2009-May. 2010      
  15                                                                                          Long-term investigation of resveratrol on management of metabolic syndrome, osteoporosis and inflammation                                          \-         NCT01412645   Resveratrol           Metabolic syndrome                    Completed                Aug. 2011-Aug. 2013      
  16                                                                                          The effects of resveratrol supplementation on measurements of health and human performance                                                         \-         NCT01244360   Resveratrol           Healthy volunteer                     Unknown                  Nov. 2010-               
  17                                                                                          Potential beneficial effects of resveratrol on obesity, metabolic syndrome and inflammation                                                        \-         NCT01150955   Resveratrol           Metabolic syndrome; Obesity           Completed                Oct. 2010-Nov. 2011      
  Studies on other metabolic diseases (disorders) at phase IV                                                                                                                                                                                                                                                                                                                           
  18                                                                                          Effect of resveratrol on improving insulin sensitivity and preserving beta cell function following gestational diabetes                            IV         NCT01997762   Resveratrol           Gestational diabetes                  Unknown                  May 2014-                
  19                                                                                          Effects of simvastatin and micronized trans-resveratrol treatment on polycystic ovary syndrome (PCOS) patients                                     IV         NCT02766803   SRT501; Simvastatin   PCOS; Insulin resistance              Recruiting               May 2016-                
  Studies on other newly developed potent SIRT1 activators                                                                                                                                                                                                                                                                                                                              
  20                                                                                          A phase II study to assess the safety, tolerability, and activity of oral SRT2104 capsules administered in type 2 diabetes subjects                II         NCT01018017   SRT2104               Type 2 diabetes                       Completed                Mar. 2010-Dec. 2010      
  21                                                                                          A phase II study to assess the safety and pharmacokinetics of SRT2104 in type 2 diabetic human subjects                                            II         NCT00937326   SRT2104               Type 2 diabetes                       Completed                Aug. 2009-Sep. 2010      
  22                                                                                          A phase I study in healthy male volunteers to investigate different doses of SRT3025 for the treatment of metabolic diseases                       I          NCT01340911   SRT3025               Healthy volunteer                     Completed                Jun. 2011-Feb. 2012      
  23                                                                                          A phase I study to assess the pharmacokinetics of SRT2104 administered as an oral suspension or capsule formulation to normal healthy volunteers   I          NCT00938275   SRT2104               Healthy volunteer                     Completed                Jan. 2009-Mar. 2009      
  24                                                                                          A phase I study to assess the pharmacokinetics, safety and tolerability of SRT2104 administered to normal healthy male volunteers                  I          NCT00933062   SRT2104               Healthy volunteer                     Completed                Mar. 2009-May 2009       
  25                                                                                          Evaluation of the pharmacokinetics and the absolute bioavailability of SRT2104 in healthy male subjects                                            I          NCT00937872   SRT2104               Healthy volunteer                     Completed                Nov. 2008-Dec. 2008      
  26                                                                                          A phase I study to assess the safety of oral SRT2104 and its effects on vascular dysfunction in healthy and type 2 diabetes subjects               I          NCT01031108   SRT2104               Type 2 diabetes                       Completed                May 2010-Oct. 2011       
  27                                                                                          A phase I study to assess the safety and pharmacokinetics of SRT2104 in normal healthy male volunteers                                             I          NCT00933530   SRT2104               Healthy volunteer                     Completed                May 2008-Nov. 2008       
  28                                                                                          A phase I study to assess the safety and pharmacokinetics of SRT2379 in normal healthy male volunteers                                             I          NCT01018628   SRT2379               Healthy volunteer                     Completed                Dec. 2009-Aug. 2010      
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